Blueprint Medicines Total Assets 2014-2021 | BPMC

Blueprint Medicines total assets from 2014 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Blueprint Medicines total assets for the quarter ending September 30, 2021 were $1.477B, a 5.19% decline year-over-year.
  • Blueprint Medicines total assets for 2020 were $1.718B, a 142.82% increase from 2019.
  • Blueprint Medicines total assets for 2019 were $0.708B, a 31.02% increase from 2018.
  • Blueprint Medicines total assets for 2018 were $0.54B, a 24.54% decline from 2017.
Blueprint Medicines Annual Total Assets
(Millions of US $)
2020 $1,718
2019 $708
2018 $540
2017 $716
2016 $283
2015 $179
2014 $50
2013 $4
Blueprint Medicines Quarterly Total Assets
(Millions of US $)
2021-09-30 $1,477
2021-06-30 $1,569
2021-03-31 $1,625
2020-12-31 $1,718
2020-09-30 $1,558
2020-06-30 $817
2020-03-31 $914
2019-12-31 $708
2019-09-30 $738
2019-06-30 $807
2019-03-31 $545
2018-12-31 $540
2018-09-30 $606
2018-06-30 $665
2018-03-31 $664
2017-12-31 $716
2017-09-30 $420
2017-06-30 $445
2017-03-31 $253
2016-12-31 $283
2016-09-30 $168
2016-06-30 $187
2016-03-31 $206
2015-12-31 $179
2015-09-30 $195
2015-06-30 $204
2015-03-31 $56
2014-12-31 $50
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.545B $0.794B
Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90